Monte Rosa Therapeutics Inc's Customers Performance

Name: Monte Rosa Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

GLUE

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


GLUE's Source of Revenues		During the corresponding time, Monte Rosa Therapeutics Inc saw a revenue deteriorated by -61.33 % year on year, sequentially revenue grew by 113.02 %. While revenue at the Monte Rosa Therapeutics Inc 's corporate clients • List of GLUE Customers

for the same period Monte Rosa Therapeutics Inc revnue deteriorated by -61.33 % year on year, sequentially revenue grew by 113.02 %.

• List of GLUE Customers

Monte Rosa Therapeutics Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Monte Rosa Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Monte Rosa Therapeutics Inc Contracts

Monte Rosa Therapeutics Unveils Promising Preclinical Data at Digestive Disease Week 2024, Propelling Excitement for a Revolutionary Treatment for Inflammatory Bowel Disease.

Monte Rosa Therapeutics Presents Promising Preclinical Data at Digestive Disease Week 2024, Showcasing the Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseIn a significant development in the field of inflammatory bowel disease (IBD) research, Monte Rosa Therapeutics, a leading biotechnology company, has presented compelling preclinical data at Digestive Disease Week 2024. The data underscores the therapeutic potential of their novel drug candidate, MRT-6160, for the treatment of IBD.IBD is a chronic condition that affects millions of people worldwide, causing inflammation and damage to the gastrointestinal tract. Current treatment options, such as immunosuppressive drugs and anti-inflammatory ...

Unleashing the Potential: Monte Rosa Therapeutics Takes on Inflammatory Diseases with MRT-8102, a Molecular Glue Degrader and Pathway Inhibitor

Monte Rosa Therapeutics Initiates IND Enabling Studies for MRT-8102: A Groundbreaking Molecular Glue Degrader and NLRP3/IL-1 Pathway InhibitorMonte Rosa Therapeutics, a leading biopharmaceutical company, has recently announced the initiation of Investigational New Drug (IND) enabling studies for their groundbreaking compound, MRT-8102. This novel drug is a first-in-class NEK7-directed molecular glue degrader and NLRP3/IL-1 pathway inhibitor. The initiation of these studies marks a significant milestone in the development of potential treatments for a variety of inflammatory diseases.MRT-8102 holds immense promise for patients suffering from diseases related to the NLRP3/IL-1 pathway. This pathway plays a cri...

GLUE's Stock Performance relative to it's Customers

GLUE's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Monte Rosa Therapeutics Inc	1,431.87	42.95	-130.01	150
SUBTOTAL	0.00	0.00	0.00	-

Sources: Monte Rosa Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Monte Rosa Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Monte Rosa Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.